Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer
Latest Information Update: 23 May 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 17 May 2024 Planned End Date changed from 30 Jun 2025 to 31 Dec 2024.
- 17 May 2024 Planned primary completion date changed from 30 Jun 2025 to 31 Dec 2024.
- 04 Jan 2024 Status changed from recruiting to active, no longer recruiting.